丁丙诺啡-纳洛酮与缓释纳曲酮在阿片戒断治疗后的比较
该观察性比较效果研究采用目标试验模拟框架,利用马萨诸塞州公共卫生数据仓库的个体链接行政数据,纳入2014年1月1日至2018年12月31日因医疗管理阿片戒断(MMOW)出院、年龄≥18岁的成人,比较出院28天内启动丁丙诺啡-纳洛酮或缓释纳曲酮的效果。调整后24周全因死亡率两组均为1.4%(风险差0.0个百分点,95%CI -0.4至0.4),非致死性阿片过量累积发生率丁丙诺啡-纳洛酮组11.6% vs 缓释纳曲酮组13.9%(风险差2.3个百分点,95%CI 1.2-3.6)。结论:MMOW出院后启动丁丙诺啡-纳洛酮与较低的24周非致死性阿片过量风险相关,但全因死亡率相似。
要点
- 调整后24周非致死性阿片过量累积发生率:丁丙诺啡-纳洛酮11.6%(95%CI 10.8%-12.3%),缓释纳曲酮13.9%(95%CI 12.9%-15.0%),风险差2.3个百分点(95%CI 1.2-3.6)。
- 调整后24周全因死亡率:丁丙诺啡-纳洛酮1.4%(95%CI 1.2%-1.7%),缓释纳曲酮1.4%(95%CI 1.1%-1.8%),风险差0.0个百分点(95%CI -0.4至0.4)。
- 研究采用目标试验模拟框架,逆概率加权调整基线和时变混杂,模仿缓释纳曲酮与丁丙诺啡治疗阿片使用障碍的随机临床试验方案。
- 该研究为观察性比较效果研究,非随机对照试验,结果需结合原文局限解读。
适用人群与场景
- 纳入:2014年1月1日至2018年12月31日在马萨诸塞州因医疗管理阿片戒断(MMOW)出院、年龄18岁及以上的成人,个体可多次符合纳入标准。
- 排除:原文未提及具体排除标准。
- 场景:MMOW出院后门诊或社区启动阿片使用障碍药物治疗,非急诊/ICU抢救场景。
诊断标准与关键阈值
- 医疗管理阿片戒断(MMOW)出院:原文未提及具体诊断标准或评分界值。
- 暴露定义:MMOW出院后28天内启动丁丙诺啡-纳洛酮或缓释纳曲酮治疗。
- 主要结局:24周全因死亡率和非致死性阿片过量的累积发生率。
处置流程与药物剂量
- 原文未提及丁丙诺啡-纳洛酮的具体剂量、给药途径、频次或疗程。
- 原文未提及缓释纳曲酮的具体剂量、给药途径、频次或疗程。
- 暴露仅为MMOW出院后28天内启动丁丙诺啡-纳洛酮或缓释纳曲酮,未给出具体启动方案或目标值。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。
研究设计与关键结果
- 研究类型:观察性比较效果研究,采用目标试验模拟框架,利用马萨诸塞州公共卫生数据仓库个体链接行政数据,模仿缓释纳曲酮vs丁丙诺啡治疗阿片使用障碍随机临床试验方案。
- 主要终点:调整后24周全因死亡率丁丙诺啡-纳洛酮1.4%(95%CI 1.2%-1.7%)vs 缓释纳曲酮1.4%(95%CI 1.1%-1.8%),风险差0.0个百分点(95%CI -0.4至0.4)。
- 关键次要终点:调整后24周非致死性阿片过量累积发生率丁丙诺啡-纳洛酮11.6%(95%CI 10.8%-12.3%)vs 缓释纳曲酮13.9%(95%CI 12.9%-15.0%),风险差2.3个百分点(95%CI 1.2-3.6)。
- 不良事件:原文未提及除死亡和非致死性阿片过量以外的其他不良事件。
证据类型、等级与局限
- 证据类型:观察性比较效果研究(目标试验模拟),非随机对照试验。
- 证据等级或推荐强度:原文未提及。
- 局限:观察性设计,依赖行政数据,可能存在未测量混杂;单州数据;暴露定义基于28天内启动治疗;原文未提及其他局限。
对床旁实践的改变
- 对于MMOW出院后的成人阿片使用障碍患者,启动丁丙诺啡-纳洛酮较缓释纳曲酮与更低的24周非致死性阿片过量风险相关(风险差2.3个百分点),全因死亡率无差异。
- 该结果支持在MMOW出院后优先考虑丁丙诺啡-纳洛酮以降低非致死性阿片过量风险,但需注意研究为观察性设计,不能推断因果。
- 不适用人群:原文未明确排除人群,但研究仅纳入马萨诸塞州18岁及以上MMOW出院成人,不能外推至其他地区、未成年人或非MMOW出院人群。
- 常见陷阱:不能将观察性风险差直接作为治疗效果的因果证据;不能将研究中的暴露启动率(13.4% vs 4.5%)误读为推荐使用率。
指南或共识出处
- 原文未提及指南或共识名称;研究数据来源为马萨诸塞州公共卫生数据仓库。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Buprenorphine-naloxone and extended-release (XR) naltrexone are both efficacious medications for opioid use disorder that reduce unregulated opioid use and improve opioid cravings and treatment retention. While prior comparative effectiveness studies demonstrated superiority of buprenorphine-naloxone over XR naltrexone for relapse and treatment retention, the comparative effectiveness of both treatments for all-cause mortality and nonfatal opioid overdose outcomes has not been rigorously tested.
OBJECTIVE: To compare the effectiveness of buprenorphine-naloxone vs XR naltrexone after medically managed opioid withdrawal (MMOW) treatment.
DESIGN, SETTING, AND PARTICIPANTS: This observational comparative effectiveness study using a target trial emulation framework leveraged individually linked administrative data from the Massachusetts Public Health Data Warehouse to emulate the protocol of the Extended-Release Naltrexone vs Buprenorphine for Opioid Treatment randomized clinical trial. Participants included adults 18 years or older who were discharged from MMOW in Massachusetts between January 1, 2014, and December 31, 2018. Individuals could meet eligibility criteria more than once. Data were analyzed from December 22, 2023, to January 30, 2025.
EXPOSURES: Initiation of buprenorphine-naloxone or XR naltrexone therapy within 28 days of MMOW discharge.
MAIN OUTCOMES AND MEASURES: Estimated 24-week cumulative incidence of all-cause mortality and nonfatal opioid overdose using inverse probability weighting to adjust for baseline and time-varying confounding.
RESULTS: A total of 36 752 unique individuals who met eligibility criteria were identified and contributed 106 052 MMOW discharge episodes; 79 089 (74.6%) episodes were among individuals who were male and 44 463 (42.1%) were among individuals aged 18 to 29 years. By 28 days after MMOW discharge, initiation of buprenorphine-naloxone was observed among 14 194 discharge episodes (13.4%) and initiation of XR naltrexone was observed among 4734 (4.5%) episodes. The adjusted 24-week cumulative incidence of all-cause mortality after MMOW discharge was 1.4% (95% CI, 1.2%-1.7%) for buprenorphine-naloxone and 1.4% (95% CI, 1.1%-1.8%) for XR naltrexone, corresponding to a risk difference of 0.0 percentage points (pp) (95% CI, -0.4 to 0.4 pp). The adjusted 24-week cumulative incidence of nonfatal opioid overdose after MMOW discharge was 11.6% (95% CI, 10.8%-12.3%) for buprenorphine-naloxone and 13.9% (95% CI, 12.9%-15.0%) for XR naltrexone, corresponding to a risk difference of 2.3 pp (95% CI, 1.2-3.6 pp).
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study of buprenorphine-naloxone vs XR naltrexone, initiating buprenorphine-naloxone after MMOW discharge was associated with a lower risk of nonfatal opioid overdose at 24 weeks than initiating XR naltrexone, but a similar risk of all-cause mortality.
参考来源
- Hsu HE, Lodi S, Yan S, et al. Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment. JAMA Netw Open. 2026. PMID: 42446876. doi:10.1001/jamanetworkopen.2026.23280
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。